NEW YORK (GenomeWeb) – Parent Project Muscular Dystrophy today announced it has granted $250,000 to University of Texas Southwestern Medical Center researcher Eric Olson for his study of a CRISPR/Cas9-based treatment for Duchenne muscular dystrophy (DMD).

Olson said in a statement that he would use the funding to test the effectiveness and safety of CRISPR in animal models of DMD. The lab will study dystrophin proteins produced using genome editing in mice and compare them to dystrophin produced by other therapeutic approaches, such as gene transfer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.